RxDoctor Payments Data

Carlos Mego, MD

Cardiovascular Disease · McAllen, TXNPI 1306869888

Payments from drug & device makers

$9,241in general payments, 2019–2025

Across 246 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Terumo Medical Corporation$1K
  • E.r. Squibb & Sons, L.L.C.$801
  • Biotronik Inc.$714
  • Merck$627
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$2503%
  • Travel & lodging$7598%
  • Food & beverage$8,15788%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,241 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$115,864
Medicare patients
378
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$253,624
EntrestoSacubitril/Valsartan163$232,384
XareltoRivaroxaban111$102,640
Repatha SureclickEvolocumab25$15,411
FarxigaDapagliflozin Propanediol12$10,519
BrilintaTicagrelor19$9,761
Ranolazine ErRanolazine83$8,045
Metoprolol Succinate436$6,944
ClopidogrelClopidogrel Bisulfate227$2,666
Cilostazol72$1,910
Amlodipine Besylate201$1,350
Olmesartan Medoxomil53$1,119
Amiodarone Hcl43$1,093
Digoxin35$1,019
Telmisartan58$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$381$253,624206 claims
NovartisEntresto$59$232,384163 claims
Johnson & JohnsonXarelto$216$102,640111 claims
AstraZenecaFarxiga, Brilinta$87$20,28031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →